I agree with your basic premise here but I'm not sure disposing of the Brilacidin IBD component too easily to further Kevetrin is necessarily the best way forward. I certainly hope the promise of Kevetrin can be developed but the Brilacidin potential seems too great to be let go lightly. Are these some of the considerations being done by the company at this time? Not decisions I would want to have to make.